DIARYL-MAKROCYCLEN-POLYMORPH

European patent · EP3319969 · In force

Register entry

Publication number
EP3319969
Application number
EP16821872
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jul 5, 2016
Published
May 16, 2018
Granted
Apr 3, 2024
Protection ends at the latest
Jul 4, 2036
Next annual fee due
Jul 31, 2027
IPC classes
C07D 491/16 (2006.01)
A61K 31/519 (2006.01)
A61K 31/52 (2006.01)
C07D 491/12 (2006.01)
C07D 491/18 (2006.01)
C07D 498/18 (2006.01)
Priority
US 201562188846 P 06.07.2015
US 201562218672 P 15.09.2015
PCT application
PCT/US2016/040972 05.07.2016
PCT publication
WO2017/007759 12.01.2017
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Aug 1, 2026

    Next annual fee due on

    Next annual fee due on
    31.07.2026 → 31.07.2027

    Published in Swissreg on 01.08.2026

  2. Aug 1, 2025

    Next annual fee due on

    Next annual fee due on
    31.07.2025 → 31.07.2026

    Published in Swissreg on 01.08.2025

  3. Feb 12, 2025

    Change

    Published in Swissreg on 12.02.2025

  4. Aug 1, 2024

    Change

    Published in Swissreg on 01.08.2024

  5. Apr 8, 2024

    Agent entered

    Representative
    Servopatent GmbH, Bühlstrasse 1, 8125 Zollikerberg

    Published in Swissreg on 08.04.2024

  6. Apr 3, 2024

    Granted

    Published in Swissreg on 03.04.2024

Parties

Holder

Turning Point Therapeutics, Inc.

3580 Carmel Mountain Road, San Diego, CA 92130, US

Agent

Servopatent GmbH

Bühlstrasse 1, 8125 Zollikerberg

Inventor

CUI, Jingrong J.

San Diego, California 92121, US

ROGERS, Evan W.

San Diego, California 92121, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.